These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 10371531)

  • 1. I.v. immunoglobulin reduces circulating proinflammatory cytokines in Guillain-Barré syndrome.
    Sharief MK; Ingram DA; Swash M; Thompson EJ
    Neurology; 1999 Jun; 52(9):1833-8. PubMed ID: 10371531
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravenous immunoglobulin reduces serum tumor necrosis factor alpha in patients with Guillain-Barre syndrome.
    Reuben S; Sumi MG; Mathai A; Nair MD; Radhakrishnan VV
    Neurol India; 2003 Dec; 51(4):487-9. PubMed ID: 14742928
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Circulating tumour necrosis factor alpha & soluble TNF receptors in patients with Guillain-Barre syndrome.
    Radhakrishnan VV; Sumi MG; Reuben S; Mathai A; Nair MD
    Indian J Med Res; 2003 May; 117():216-20. PubMed ID: 14609050
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating transforming growth factor beta 1 (TGF-beta1) in Guillain-Barré syndrome: decreased concentrations in the early course and increase with motor function.
    Créange A; Bélec L; Clair B; Degos JD; Raphaël JC; Gherardi RK
    J Neurol Neurosurg Psychiatry; 1998 Feb; 64(2):162-5. PubMed ID: 9489524
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pro-inflammatory cytokines, lymphocyte subsets and intravenous immunoglobulin therapy in Guillain-Barré syndrome.
    Tekgül H; Kütükçüler N; Cağlayan S; Tütüncüoğlu S
    Turk J Pediatr; 1998; 40(3):357-63. PubMed ID: 9763899
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Value of intravenous immunoglobulins. A case of Guillain-Barré syndrome].
    Hidou M; Olivier J; Vivant JF
    Rev Neurol (Paris); 1992; 148(11):706-8. PubMed ID: 1303562
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of IVIg therapy on serum levels of neuropeptide Y and cytokines in Guillain-Barré syndrome.
    Li C; Luo T; Cheng Y; Liu S; Qiao L; Wu X; Liu K
    Neurol Sci; 2020 Feb; 41(2):295-303. PubMed ID: 31494821
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulatory T cell frequency, but not plasma IL-33 levels, represents potential immunological biomarker to predict clinical response to intravenous immunoglobulin therapy.
    Maddur MS; Stephen-Victor E; Das M; Prakhar P; Sharma VK; Singh V; Rabin M; Trinath J; Balaji KN; Bolgert F; Vallat JM; Magy L; Kaveri SV; Bayry J
    J Neuroinflammation; 2017 Mar; 14(1):58. PubMed ID: 28320438
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndrome. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group.
    Lancet; 1997 Jan; 349(9047):225-30. PubMed ID: 9014908
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Efficacy of Intravenous Immunoglobulin in Guillain-Barré Syndrome: The Experience of a Tertiary Medical Center.
    Shalem D; Shemer A; Shovman O; Shoenfeld Y; Kivity S
    Isr Med Assoc J; 2018 Dec; 20(12):754-760. PubMed ID: 30550005
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma exchange versus intravenous immunoglobulin for Guillain-Barré syndrome.
    Hughes RA
    Ther Apher; 1997 May; 1(2):129-30. PubMed ID: 10225757
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum tumour necrosis factor-alpha and soluble tumour necrosis factor receptors levels in patients with Guillain-Barre syndrome.
    Radhakrishnan VV; Sumi MG; Reuben S; Mathai A; Nair MD
    Acta Neurol Scand; 2004 Jan; 109(1):71-4. PubMed ID: 14653854
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Treatment of Guillain-Barré syndrome with high-dose intravenous immunoglobulins--a comparison with plasma exchange].
    Kamei T; Nakagawa H; Uchiyama F; Fukuyama J
    Rinsho Shinkeigaku; 1993 Jun; 33(6):660-2. PubMed ID: 8403689
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IgG Fc N-glycosylation in Guillain-Barré syndrome treated with immunoglobulins.
    Fokkink WJ; Selman MH; Dortland JR; Durmuş B; Kuitwaard K; Huizinga R; van Rijs W; Tio-Gillen AP; van Doorn PA; Deelder AM; Wuhrer M; Jacobs BC
    J Proteome Res; 2014 Mar; 13(3):1722-30. PubMed ID: 24533874
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of immunotherapy in Guillain-Barré syndrome: understanding the mechanism of action.
    Shahrizaila N; Yuki N
    Expert Opin Pharmacother; 2011 Jul; 12(10):1551-60. PubMed ID: 21473704
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravenous immunoglobulins neutralize blocking antibodies in Guillain-Barré syndrome.
    Buchwald B; Ahangari R; Weishaupt A; Toyka KV
    Ann Neurol; 2002 Jun; 51(6):673-80. PubMed ID: 12112071
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison between IVIg and plasma exchange in Guillain-Barré syndrome: a review and decision analysis of the two treatment modalities.
    Dawson WB; Phillips LH
    Clin Neuropharmacol; 1995 Oct; 18(5):377-90. PubMed ID: 8665552
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating tumor necrosis factor (TNF)-alpha and soluble TNF-alpha receptors in patients with Guillain-Barré syndrome.
    Créange A; Bélec L; Clair B; Raphaël JC; Gherardi RK
    J Neuroimmunol; 1996 Aug; 68(1-2):95-9. PubMed ID: 8784265
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single dose immunoglobulin therapy for childhood Guillain-Barré syndrome.
    Zafeiriou DI; Kontopoulos EE; Katzos GS; Gombakis NP; Kanakoudi FG
    Brain Dev; 1997 Jul; 19(5):323-5. PubMed ID: 9253484
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pilot trial of immunoglobulin versus plasma exchange in patients with Guillain-Barré syndrome.
    Bril V; Ilse WK; Pearce R; Dhanani A; Sutton D; Kong K
    Neurology; 1996 Jan; 46(1):100-3. PubMed ID: 8559353
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.